TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)
Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ — TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs for unmet medical needs, is currently seeking participants for a Phase 1 clinical trial … Read more